Inventiva S.A.

IVA

Biotechnology · Healthcare

Also trades as: IVA.PA · 0RNK.L

Price

$4.68

+0.03 (+0.65%)

Market Cap

$243.3M

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Dec 31, 2025

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+376.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 39.2M (2021) → 186.8M (2025)

Winston Score History

The full picture

Inventiva is a French biotechnology company that discovers and develops drugs for diseases that currently have few or no good treatments. Its main focus is on a condition called MASH (metabolic dysfunction-associated steatohepatitis), which is a serious liver disease linked to obesity and diabetes. The company's lead drug candidate is lanifibranor, which has shown promising results in clinical trials targeting this liver condition.

Inventiva makes money primarily through research partnerships, licensing agreements, and grants rather than selling approved products yet. It is based in Daix, France, and operates mainly in Europe, though its clinical trials are international in scope. With a market cap of around $200 million and a deeply negative operating margin, the company is still in the pre-revenue drug development stage, spending heavily on research. The key risk is that lanifibranor must successfully complete regulatory approval — failure at that stage would significantly threaten the company's future.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-99.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+89.2% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

€84M/ year

↓ Declining (-8% vs prior year)

>1,000% of revenue

103.6x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

15.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~5 months

€100M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Inventiva S.A. has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-4062.1%

Thin — -4062.1% gross margin

Profit after running costs

Operating Margin

-257580.5%

Losing money on operations — -257580.5%

Return on the money invested

ROCE

-285.1%

Weak — -285.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-51.3%

Shrinking sales (-51.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-2418.1%

Burning cash (-2418.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial